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Objective/background: Evaluate changes in insomnia severity in subjects with moderate to severe
insomnia (Insomnia Severity Index [ISI] score 15) treated for 12 months nightly with lemborexant.
Patients/methods: This phase 3 randomized study comprised two 6-month treatment periods. In
Period 1, 949 subjects were randomized to placebo, lemborexant 5 mg (LEM5) or 10 mg (LEM10). In
Period 2, placebo subjects were rerandomized to LEM5 or LEM10; subjects initially randomized to
lemborexant continued their assigned treatment. Insomnia severity was assessed using baseline ISI and
1-, 3-, 6-, 9-, and 12-month post-treatment scores.
Results: Mean ISI scores improved signiﬁcantly across treatment groups and disease severities, with
greater decreases from baseline in the LEM5 and LEM10 versus placebo groups at months 1
(7.1, 7.2, 5.2, respectively), 3 (8.6, 8.9, 6.1, respectively), and 6 (9.9, 9.8, 7.2 respectively); ISI
score improvements were maintained with LEM5 and LEM10 at months 9 (11.1 and 11.2, respectively)
and 12 (11.5 and 11.2, respectively). At months 1, 3, and 6, signiﬁcantly more treatment responders
(7-point ISI score decrease from baseline) were observed with LEM5 (44%e57%) and LEM10 (44%e52%)
versus placebo (30%e41%). At months 1, 3, and 6, more remitters (ISI total score <10 and < 8) were
observed with LEM5 (30%e44% and 22%e34%, respectively) and LEM10 (31%e41% and 22%e31%,
respectively) versus placebo (18%e28% and 11%e21%, respectively).
Conclusions: Lemborexant signiﬁcantly reduced insomnia severity for 12 months and increased clinically
meaningful response and remission rates versus placebo.
Clinical trial registration: ClinicalTrials.gov, NCT02952820; ClinicalTrialsRegister.eu, EudraCT Number
2015-001463-39.
© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords:
Insomnia
Lemborexant
Orexin
Pharmacotherapy
Insomnia Severity Index

1. Introduction
Insomnia, a disorder characterized by difﬁculties in falling
asleep and/or staying asleep, and impaired daytime function or

Abbreviations: DORA, dual orexin receptor antagonist; DSM-5, Diagnostic and
Statistical Manual of Mental Disorders, ﬁfth edition; FAS, Full Analysis Set; ISI,
Insomnia Severity Index; LEM5, lemborexant 5 mg; LEM10, lemborexant 10 mg.
* Corresponding author.
E-mail address: Margaret_Moline@eisai.com (M. Moline).
1
Former employee.

distress is the most common sleep-wake disorder [1]. While
insomnia has been shown to negatively impact overall health and
increase health care utilization [2e4], severity of insomnia (ie, the
severity of both nighttime symptoms and associated daytime
functional impairments) has also been shown to be an important
health determinant. In studies over the past 10 years, more severe
insomnia has been associated with diminished well-being and
quality of life; increased anxiety, depression, and suicidal ideation;
increased use of alcohol; reduced likelihood of remission from
major depressive disorder; greater use of health care resources;
increased health care costs; and increased physical symptoms

https://doi.org/10.1016/j.sleep.2022.01.024
1389-9457/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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although at the approved doses of suvorexant, ISI results are only
available from 1-month or 3-month measurements [29e32]. The
ISI can also be used to deﬁne treatment responders and remitters
[24]. Treatment response may be determined using empirically
validated ISI criteria for the minimally important difference in
symptomatology, whereas remission can be operationalized as a
reduction in symptoms to subclinical levels [24,34].
Certainly, many studies demonstrate absolute post-treatment
differences in ISI scores as a measure of treatment efﬁcacy; however, few studies evaluate responder and remission rates in patients
with insomnia. Perhaps most responder and remitter analyses have
been done in benzodiazepine-treated patients with insomnia. In
these studies, modest improvements are generally reported relative
to placebo. For example, one study evaluating nightly treatment of
primary insomnia for 6 months found that in addition to improving
subjective sleep measures, eszopiclone signiﬁcantly reduced
insomnia severity to below clinically meaningful levels (ISI 14) in
50% of patients (vs 19% with placebo) [27]. In a similar study, patients with primary insomnia demonstrated that in addition to
improving various subjective sleep measures (eg, total sleep time,
wake after sleep onset), 3 months of treatment with indiplon
resulted in signiﬁcantly more patients meeting the responder
criteria (Investigator Global Rating of Change score 2; ~55% vs 30%)
and ISI remission criteria (ISI <11) compared with placebo (53%e
55% vs 40%) [35]. More recently, a study to measure the effectiveness
of benzodiazepine receptor antagonists in the treatment of
insomnia found that although 76.7% responded to treatment (ISI
score change 6 points), only 47.7% achieved remission (ISI <11)
[36]. Similar analyses have been reported with the DORA, suvorexant. A pooled analysis of two phase 3 studies found higher
responder (ISI 6-point improvement) rates with suvorexant
compared with placebo at 1 (33.9% vs 22.9%) and 3 months (55.5% vs
42.2%) post-treatment; remitter analyses were not reported [31].
This paper presents prespeciﬁed and post-hoc analyses from
subjects in Study 303 (E2006-G000-303; SUNRISE-2; NCT02952820)
who reported moderate to severe insomnia at baseline (ISI total
score 15). The analyses explore the question of whether nightly
dosing of lemborexant for up to 1 year improves insomnia severity.
This is the ﬁrst long-term study of a DORA at approved therapeutic
dosages on insomnia severity.

including pain and fatigue [5e13]. Studies also showed that reductions in insomnia severity were associated with reductions in
the severity of comorbid conditions, such as depression [14].
Together, these studies suggest that improvements in insomnia
disorder severity are an important consideration in the care of
patients with insomnia.
Current treatment options for insomnia include cognitive
behavioral therapy, sedative-hypnotic benzodiazepines and nonbenzodiazepines, melatonin receptor agonists, sedating antidepressants, sedating antihistamines, and dual orexin receptor
antagonists (DORAs) [15]. Sleep-promoting therapies have typically
been assessed based on their effect on nocturnal symptom endpoints (ie, total sleep time, sleep latency, and wake after sleep onset
as measured by polysomnography and patient reports) [15].
Insomnia is characterized by physiological and cognitive
hyperarousal, both of which likely contribute to the inability to
initiate and/or maintain sleep [16]. The orexin neuropeptide
signaling system is involved in the regulation of arousal and
wakefulness [17]. Thus, orexin receptor antagonism may serve as a
therapeutic mechanism to manage sleep disturbances speciﬁcally
and insomnia disorder severity overall. However, no studies have
been published to date that examine the long-term beneﬁt of
orexin receptor antagonists at therapeutic dosages on insomnia
severity, as assessed by the Insomnia Severity Index (ISI), for up to
12 months.
Lemborexant is a DORA approved in multiple countries,
including the United States, Japan, Canada, Australia, and several
Asian countries for the treatment of adults with insomnia. Lemborexant is a competitive antagonist at orexin receptor types 1 and
2 [18]; therefore, as a DORA, lemborexant reduces wakefulness by
attenuating orexin-mediated wake drive. The efﬁcacy and safety of
lemborexant in insomnia disorder were examined in two pivotal
phase 3 clinical studies. In these studies, patient-reported (sleep
diary) sleep measures, including larger and statistically signiﬁcant
decreases in sleep onset latency and wake after sleep onset, were
observed over 6 months comparing lemborexant with placebo [19].
The beneﬁts of lemborexant were maintained across 12 months of
nightly treatment [20]. A second phase 3 study, E2006-G000-304
(SUNRISE-1; NCT02783729), demonstrated signiﬁcant beneﬁt of
lemborexant on polysomnographic measures of sleep onset and
maintenance compared with placebo and zolpidem tartrate
extended release over 1 month [21]. Lemborexant was well tolerated in both studies, with the majority of treatment-emergent
adverse events as mild or moderate in severity [19e21]. These
endpoints typically reﬂect the outcome on a particular endpoint (ie,
nocturnal insomnia symptoms), which are more an index of
improvement in nocturnal sleep than insomnia disorder severity.
Importantly, insomnia disorder is more than a nocturnal disorderdit is associated with concurrent daytime impairments [22].
As a diagnosis of insomnia disorder is symptom-based, patientreported outcomes provide a valid measure of treatment efﬁcacy.
The severity of insomnia is routinely assessed using the self-report
ISI questionnaire [23]. The ISI is a reliable and validated instrument
[24] that assesses the severity of insomnia based on patients’
symptoms and their associated impact on sleep patterns, interpersonal factors, daily functioning, and worry or distress, factors
that are all considered in the Diagnostic and Statistical Manual of
Mental Disorders, ﬁfth edition (DSM-5) [22] diagnostic criteria of
chronic insomnia. Previous research has utilized the ISI to assess
improvement in insomnia severity after treatment with sleeppromoting agents. For example, greater improvements on the ISI
have been observed with doxepin [25] and eszopiclone [26,27]
compared with placebo over 3 months and 6 months, respectively.
In addition, several analyses demonstrated improvement in mean
ISI total scores with the DORA suvorexant versus placebo [28e33],

2. Methods
2.1. Study design
This report is based on prespeciﬁed and post-hoc analyses of
data from Study 303. Complete study details including enrollment
criteria, primary endpoints, and key secondary endpoints have
been reported previously [19]. Brieﬂy, Study 303 was a 12-month,
randomized, double-blind, placebo-controlled (ﬁrst 6 months
[Treatment Period 1]), active-only (last 6 months [Treatment Period
2]) parallel-group study.
Study drug was administered following an approximate 2-week
single-blind placebo run-in. The lemborexant doses were 5 mg
(LEM5) and 10 mg (LEM10). Subjects who received placebo during
Treatment Period 1 were rerandomized approximately 1:1 to LEM5
or LEM10 during Treatment Period 2; these subjects were not
included in the analyses. Efﬁcacy and safety outcomes for subjects
rerandomized from placebo to lemborexant for Treatment Period 2
will be reported separately.
The study was approved by an independent Institutional Review
Board and conducted in accordance with International Council for
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use guidelines, Good Clinical Practice
Guidelines, the Declaration of Helsinki, and local regulations.
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T. Roth, R. Rosenberg, C.M. Morin et al.

Sleep Medicine 90 (2022) 249e257

calculated based on normal approximation, and P values for betweengroup comparisons were based on the CochraneManteleHaenszel
test stratiﬁed by region and age group.
In addition, the number and percentage of subjects in each
insomnia severity category (based on ISI total score) was calculated
at months 1, 3, 6, 9, and 12 in the FAS and in the subgroups of
subjects in the FAS who had moderate or severe insomnia at
baseline. These analyses were conducted to determine the frequency with which subjects shifted from moderate or severe
insomnia at baseline to other severity categories at each time point.

Before any screening procedures, all study subjects provided
written informed consent.
2.2. Participants
The subjects in the current study include all those in the Full
Analysis Set (FAS) from Study 303. Full details of study inclusion
and exclusion criteria have been reported [19]. All subjects met
the DSM-5 criteria for insomnia disorder [22]. The study included
males and females 18 years of age with a complaint of sleep
onset and/or sleep maintenance difﬁculties and ISI total score 15
[19]. Subjective sleep parameters for each treatment group were
conﬁrmed by sleep history, questionnaires and sleep diary, as
previously reported [19].

3. Results
3.1. Baseline characteristics

2.3. ISI

The FAS comprised 949 subjects (placebo, n ¼ 318; LEM5,
n ¼ 316; LEM10, n ¼ 315). Six hundred and ninety-two subjects had
moderate insomnia (ISI total score 15e21) at baseline, and 223
subjects had severe insomnia (ISI total score 22e28) at baseline. An
additional 34 subjects were included in the study despite not
meeting ISI inclusion criteria at baseline, as they had met the ISI
15 inclusion criterion at screening. One additional subject
(N ¼ 950) was added to some of the post-hoc analyses after ﬁnal
data reconciliation at the end of the 12-month study, as that subject's updated data met FAS criteria.
Across all severity and treatment groups, most subjects were
white and female (Table 1). Across treatment arms in the FAS, mean
ISI total score at baseline was approximately 19, indicative of
moderate insomnia [23]. Mean ISI total score was similar across
treatment groups within each insomnia severity category (Table 1).

The ISI was administered at baseline and at the end of months 1,
3, 6, 9, and 12. The dimensions evaluated by each of the ISI items
are: (1) severity of sleep onset difﬁculties; (2) sleep maintenance
difﬁculties; (3) early morning awakening problems; (4) sleep
dissatisfaction; (5) interference of sleep difﬁculties with daytime
functioning; (6) noticeability of the sleep problems by others; and
(7) distress caused by sleep difﬁculties [23].
Each item in the ISI is scored on a ﬁve-point Likert scale ranging
from 0 (no problem) to 4 (very severe problem). The ISI total score
was calculated as the sum of participant responses to items 1e7. A
score of 22e28 corresponds with severe insomnia, 15e21 with
moderate insomnia, 8e14 with subthreshold insomnia, and 0e7
with no clinically signiﬁcant insomnia [23,24].
Based on change from baseline in ISI total scores, post-hoc
responder and remitter analyses were also conducted. For the
responder analysis, the percentage of subjects with a decrease from
baseline of 7 points in ISI total score after 1, 3, 6, 9, or 12 months of
treatment was calculated. The rationale for this responder criterion
was the ﬁnding that a decrease in ISI total score >7 identiﬁed patients with moderate improvements on the ISI in a sample population [24]. Additionally, the percentage of subjects who achieved
remission from insomnia based on ISI total score <10 [24] or <8
after 1, 3, 6, 9, or 12 months of treatment was calculated. In a
sample population, a cutoff score of 10 was found to be an appropriate threshold for detecting insomnia [24]. An ISI total score of <8
aligns with the disease severity category of no clinically signiﬁcant
insomnia (ISI total score 0e7).

3.2. Change from baseline in ISI total score
Mean ISI total scores decreased from baseline across all treatment groups (Fig. 1). Decreases were signiﬁcantly greater with
LEM5 and LEM10 compared with placebo at the end of month 1
(both comparisons, P < 0.01), month 3 (both comparisons,
P < 0.0001), and month 6 (both comparisons, P < 0.0001; Fig. 1 and
Supplementary Table 1). The decreases in ISI total score with LEM5
and LEM10 were maintained after 9 and 12 months of treatment.
3.3. Responder and remitter analyses
Signiﬁcantly higher percentages of subjects achieved a decrease
from baseline in ISI total score of 7 points (ie, were treatment responders) with LEM5 and LEM10 compared with placebo at month 1
(LEM5 ¼ 44.0%; LEM10 ¼ 44.4%; placebo ¼ 29.5%; both comparisons,
P < 0.001), month 3 (LEM 5 ¼ 53.5%; LEM10 ¼ 52.1%; placebo ¼ 36.4%;
both comparisons, P < 0.0001), and month 6 (LEM5 ¼ 56.6%;
LEM10 ¼ 51.4%; placebo ¼ 41.4%; P ¼ 0.0002 and P ¼ 0.0107,
respectively; Table 2). The percentage of treatment responders was
maintained at over 50% for both doses of LEM through months 9
(LEM5 ¼ 57.3%; LEM10 ¼ 51.1%) and 12 (LEM5 ¼ 53.8%;
LEM10 ¼ 51.7%).
In addition to the responder analysis, two analyses were performed to identify subjects who achieved remission from insomnia,
deﬁned as reaching ISI total score <10 or <8. Signiﬁcantly higher
percentages of subjects with an ISI total score <10 were observed
with LEM5 and LEM10 treatment compared with placebo at month
1 (LEM5 ¼ 30.4%; LEM10 ¼ 31.1%; placebo ¼ 17.6%), month 3
(LEM5 ¼ 38.0%; LEM10 ¼ 39.4%; placebo ¼ 24.8%), and month 6
(LEM5 ¼ 44.0%; LEM10 ¼ 40.6%; placebo ¼ 27.9%) (P < 0.001 for all
comparisons; Table 2). Among subjects treated with either dose of
lemborexant, over 40% maintained remission at the level of ISI total

2.4. Statistical analyses
ISI endpoints were assessed in the Full Analysis Set (FAS) from
Study 303, deﬁned as the group of randomized subjects who
received at least one dose of study drug and had at least one
postdose ISI measurement [19]. Additional analyses, where indicated, were conducted in the subgroups of subjects from the FAS
with moderate insomnia at baseline (ISI total score 15e21) or severe insomnia at baseline (ISI total score 22e28).
Prespeciﬁed changes from baseline in ISI total score at the end of
months 1, 3, and 6 were analyzed using a mixed-effect model
repeated measurement analysis with factors for age group, region,
visit (time point), treatment, and treatment-by-visit interaction as
ﬁxed effects, and the baseline ISI total score value as a covariate.
Changes from baseline in ISI total score at the end of months 9 and
12 were summarized descriptively. Missing values were not
imputed.
For the responder and remitter analyses, study dropouts and participants with missing information were considered nonresponders.
At months 1, 3, and 6, two-sided 95% conﬁdence intervals were
251
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Table 1
Baseline demographics and characteristics.
Full Analysis Set (N ¼ 949)

Age, y
Mean (SD)
Median (range)
Sex, n (%)
Male
Female
Race, n (%)
White
Black or African
American
Asian
Other
BMI, mean (SD),
kg/m2
ISI total score,
mean (SD)
Sleep parameters
sSOL, median
(1st and 3rd
quartiles), min
sSE, mean (SD), %
sWASO, mean (SD),
sTST, mean (SD), min

Subjects with moderate insomniaa at
baseline (n ¼ 692)

Subjects with severe insomniab
at baseline (n ¼ 223)

PBO
(n ¼ 318)

LEM5
(n ¼ 316)

LEM10
(n ¼ 315)

PBO
(n ¼ 241)

LEM5
(n ¼ 222)

LEM10
(n ¼ 229)

PBO
(n ¼ 65)

LEM5
(n ¼ 84)

LEM10
(n ¼ 74)

54.5 (14.0)
56 (18e83)

54.2 (13.7)
55 (20e85)

54.8 (13.7)
55 (18e88)

54.6 (13.9)
56 (18e83)

54.8 (13.7)
56 (20e85)

54.8 (14.1)
56 (18e88)

53.9 (14.9)
55 (25e83)

52.7 (13.8)
54.5 (20e76)

55.1 (12.5)
54 (24e83)

102 (32.1)
216 (67.9)

107 (33.9)
209 (66.1)

93 (29.5)
222 (70.5)

78 (32.4)
163 (67.6)

77 (34.7)
145 (65.3)

73 (31.9)
156 (68.1)

22 (33.8)
43 (66.2)

27 (32.1)
57 (67.9)

16 (21.6)
58 (78.4)

232 (73.0)
23 (7.2)

222 (70.3)
27 (8.5)

225 (71.4)
26 (8.3)

166 (68.9)
19 (7.9)

154 (69.4)
13 (5.9)

165 (72.1)
17 (7.4)

57 (87.7)
2 (3.1)

61 (72.6)
13 (15.5)

54 (73.0)
6 (8.1)

59 (18.6)
4 (1.3)
27.2 (5.5)

61 (19.3)
6 (1.9)
27.3 (6.3)

58 (18.4)
6 (1.9)
27.2 (5.6)

54 (22.4)
2 (0.8)
27.2 (5.7)

53 (23.9)
2 (0.9)
26.9 (5.9)

45 (19.7)
2 (0.9)
27.2 (5.9)

4 (6.2)
2 (3.1)
27.4 (5.3)

6 (7.1)
4 (4.8)
28.5 (7.3)

10 (13.5)
4 (5.4)
26.9 (4.4)

19.0 (3.1)

19.6 (3.3)

19.1 (3.4)

18.2 (2.0)

18.3 (1.9)

17.9 (1.9)

23.3 (1.3)

23.8 (1.9)

23.8 (1.6)

55.9
(34.1, 78.9)

53.6
(32.9, 75.7)

55.7
(33.6, 85.1)

50.0
(32.1, 72.1)

50.4
(32.9, 71.4)

52.5
(32.5, 75.8)

71.6
(46.4, 107.1)

68.6
(45.0, 94.3)

73.6
(38.6, 105.2)

61.3 (17.8)
132.5 (80.2)
304.3 (91.5)

63.1 (18.2)
132.8 (82.5)
315.5 (93.5)

62.0 (17.2)
136.8 (87.4)
306.9 (88.0)

63.7 (16.7)
123.3 (74.7)
315.3 (86.7)

65.6 (16.0)
122.4 (73.4)
328.4 (83.8)

63.3 (16.4)
128.2 (75.6)
311.0 (83.1)

51.2 (18.5)
168.9 (91.3)
257.7 (95.8)

54.0 (21.4)
168.5 (96.9)
269.1 (106.4)

56.3 (19.6)
172.8 (113.3)
283.1 (101.7)

BMI ¼ body mass index; ISI ¼ Insomnia Severity Index; LEM5 ¼ lemborexant 5 mg; LEM10 ¼ lemborexant 10 mg; PBO ¼ placebo; SD ¼ standard deviation; sSE ¼ subjective
sleep efﬁciency; sSOL ¼ subjective sleep onset latency; sTST ¼ subjective total sleep time; sWASO ¼ subjective wake after sleep onset.
a
Moderate insomnia, ISI total score 15e21.
b
Severe insomnia, ISI total score 22e28. Of all subjects in the Full Analysis Set, 34 subjects did not meet ISI inclusion criteria at baseline (ISI total score 8e14, n ¼ 32; ISI total
score 0e7, n ¼ 2), although they met ISI inclusion criteria at screening.

PBO

LEM5

Treatment Period 1

LEM10
Treatment Period 2

0

−5

Improvement

Mean (SD) change from BL in ISI total score

5

‡*

−10

**

**

−15

−20
Month 1

Month 3

Month 6

Month 9

Month 12

Fig. 1. Change from baseline in ISI total score across 12 months of treatment (Full Analysis Set, N ¼ 949). *P < 0.0001, zP < 0.01 vs PBO. Baseline: PBO, n ¼ 318; LEM5, n ¼ 316;
LEM10, n ¼ 315. Month 1: PBO, n ¼ 296; LEM5, n ¼ 300; LEM10, n ¼ 286. Month 3: PBO, n ¼ 283; LEM5, n ¼ 274; LEM10, n ¼ 259. Month 6: PBO, n ¼ 257; LEM5, n ¼ 258; LEM10,
n ¼ 234. Month 9: LEM5, n ¼ 233; LEM10, n ¼ 205. Month 12: LEM5, n ¼ 220; LEM10, n ¼ 201. For months 1e6, P values are based on mixed-effect model repeated measurement
analysis with factors for age group, region, visit (time point), treatment, and treatment-by-visit interaction as ﬁxed effects, and baseline ISI total score value as a covariate.
BL ¼ baseline; ISI ¼ Insomnia Severity Index; LEM5 ¼ lemborexant 5 mg; LEM10 ¼ lemborexant 10 mg; PBO ¼ placebo; SD ¼ standard deviation.
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PBO (n ¼ 319)

253

Month 1
Yes, n (%)
No, n (%)
Missing, n (%)b
Difference of proportion vs
PBO (95% CI)c
P value vs PBOc,d
Month 3
Yes, n (%)
No, n (%)
Missing, n (%)b
Difference of proportion vs
PBO (95% CI)c
P value vs PBOc,d
Month 6
Yes, n (%)
No, n (%)
Missing, n (%)b
Difference of proportion vs
PBO (95% CI)c
P value vs PBOc,d
Month 9
Yes, n (%)
No, n (%)
Missing, n (%)b
Month 12
Yes, n (%)
No, n (%)
Missing, n (%)b

LEM5 (n ¼ 316)

LEM10 (n ¼ 315)

PBO (n ¼ 319)

LEM5 (n ¼ 316)

Responders: 7-point decrease in ISI total
score from baseline

Remitters: ISI total score <10

94 (29.5)
202 (63.3)
23 (7.2)

56 (17.6)
240 (75.2)
23 (7.2)

116 (36.4)
167 (52.4)
36 (11.3)

132 (41.4)
126 (39.5)
61 (19.1)

139 (44.0)
162 (51.3)
15 (4.7)
14.2 (6.7e21.6)

140 (44.4)
147 (46.7)
28 (8.9)
14.9 (7.5e22.3)

0.0002

0.0001

169 (53.5)
105 (33.2)
42 (13.3)
17.0 (9.3e24.6)

164 (52.1)
95 (30.2)
56 (17.8)
15.7 (8.1e23.4)

<0.0001

<0.0001
179 (56.6)
78 (24.7)
59 (18.7)
14.9 (7.2e22.5)

162 (51.4)
72 (22.9)
81 (25.7)
10.1 (2.4e17.9)

0.0002

79 (24.8)
204 (63.9)
36 (11.3)

89 (27.9)
169 (53.0)
61 (19.1)

LEM10 (n ¼ 315)

PBO (n ¼ 319)

LEM5 (n ¼ 316)

LEM10 (n ¼ 315)

Remitters: ISI total score <8

96 (30.4)
205 (64.9)
15 (4.7)
12.8 (6.1e19.4)

98 (31.1)
189 (60.0)
28 (8.9)
13.7 (7.1e20.3)

0.0002

<0.0001

120 (38.0)
154 (48.7)
42 (13.3)
13.0 (5.8e20.1)

124 (39.4)
135 (42.9)
56 (17.8)
14.9 (7.7e22.1)

0.0004

<0.0001
139 (44.0)
118 (37.3)
59 (18.7)
15.6 (8.3e22.9)

128 (40.6)
106 (33.7)
81 (25.7)
12.6 (5.3e20.0)

0.0107

<0.0001

181 (57.3)
52 (16.5)
83 (26.3)

161 (51.1)
46 (14.6)
108 (34.3)

170 (53.8)
50 (15.8)
96 (30.4)

163 (51.7)
41 (13.0)
111 (35.2)

36 (11.3)
260 (81.5)
23 (7.2)

54 (16.9)
229 (71.8)
36 (11.3)

66 (20.7)
192 (60.2)
61 (19.1)

69 (21.8)
232 (73.4)
15 (4.7)
10.5 (4.8e16.3)

70 (22.2)
217 (68.9)
28 (8.9)
11.1 (5.3e16.8)

0.0004

0.0002

82 (25.9)
192 (60.8)
42 (13.3)
9.1 (2.7e15.4)

92 (29.2)
167 (53.0)
56 (17.8)
12.5 (6.1e19.0)

0.0055

0.0002
106 (33.5)
151 (47.8)
59 (18.7)
12.5 (5.6e19.3)

99 (31.4)
135 (42.9)
81 (25.7)
10.6 (3.8e17.4)

0.0008

0.0004

0.0025

143 (45.3)
90 (28.5)
83 (26.3)

140 (44.4)
67 (21.3)
108 (34.3)

111 (35.1)
122 (38.6)
83 (26.3)

111 (35.2)
96 (30.5)
108 (34.3)

145 (45.9)
75 (23.7)
96 (30.4)

134 (42.5)
70 (22.2)
111 (35.2)

114 (36.1)
106 (33.5)
96 (30.4)

109 (34.6)
95 (30.2)
111 (35.2)
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Table 2
Statistical analysis of responder and remitter rates at each study timepoint (Full Analysis Set, N ¼ 950a).

CI ¼ conﬁdence interval; ISI ¼ Insomnia Severity Index; LEM5 ¼ lemborexant 5 mg; LEM10 ¼ lemborexant 10 mg; PBO ¼ placebo.
a
One patient was identiﬁed after the full database lock compared with Period 1 database lock and included in the post-hoc analysis.
b
Study dropouts and participants with missing information were considered nonresponders.
c
Two-sided 95% CI based on normal approximation.
d
P values based on CochraneManteleHaenszel test.
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score <10 at months 9 (LEM5 ¼ 45.3%; LEM10 ¼ 44.4%) and 12
(LEM5 ¼ 45.9%; LEM10 ¼ 42.5%).
In the second remitter analysis, signiﬁcantly more subjects
receiving either LEM5 or LEM10 achieved ISI total score <8 compared
with subjects receiving placebo at months 1 (LEM5 ¼ 21.8%;
LEM10 ¼ 22.2%; placebo ¼ 11.3%), 3 (LEM5 ¼ 25.9%; LEM10 ¼ 29.2%;
placebo ¼ 16.9%), and 6 (LEM5 ¼ 33.5%; LEM10 ¼ 31.4%;
placebo ¼ 20.7%) (P < 0.01 for all comparisons; Table 2). With either
dose of lemborexant, more than one-third of subjects maintained
this level of remission through months 9 (LEM5 ¼ 35.1%;
LEM10 ¼ 35.2%) and 12 (LEM5 ¼ 36.1%; LEM10 ¼ 34.6%).

3 months of treatment. A recent phase 2 study in 359 subjects of an
investigational DORA, daridorexant, found that ISI scores did not
show a dose-dependent relationship over the 1-month study
despite sustained reductions of wake after sleep onset and latency
to persistent sleep by polysomnography over the treatment
period; the absolute change in ISI score from baseline to day 30
was similar between placebo and daridorexant and smaller than
the zolpidem comparator despite objective polysomnography
measures [37]. The small sample sizes across the daridorexant
doses (5, 10, 25, 50 mg) may limit the interpretation of these
ﬁndings.
The improvement in insomnia severity and long-term remission
rates we observed with lemborexant may have signiﬁcant implications on long-term improvements in quality of life, daytime
functioning, and morbidity associated with insomnia; these variables were not evaluated in the current analysis. Limited systematic
studies have evaluated the relationship between successful longterm insomnia treatment and improvement of adverse consequences; however, of those available, most show a positive relationship. Several independent 6-month studies of pharmacologic
treatment for primary insomnia found that in addition to signiﬁcant improvement in efﬁcacy on sleep parameters, patientreported daytime alertness and concentration, ability to function
during the daytime, and physical sense of well-being improved
[27,38e40]. Improvements have also been reported in patients with
comorbid sleep disorders. One study of patients with comorbid
insomnia and rheumatoid arthritis, and another with comorbid
periodic limb disorder and excessive daytime sleepiness, showed
lower-than-optimal daytime alertness improved signiﬁcantly in
addition to improved sleep [41,42]. Similarly, a 6-month study of
eszopiclone for the treatment of chronic insomnia in patients with
and without comorbid psychiatric disorders, including major
depressive disorder and generalized anxiety disorder, demonstrated signiﬁcant long-term improvements across numerous sleep
parameters, as well as improvements in mental health scores in
patients with psychiatric comorbidities [43]. Whether the longterm remission observed with lemborexant is associated with
similar long-term improvements in conditions seen in chronic
insomnia remains to be seen. Indeed, investigation into this relationship is warranted in future studies.

3.4. Distribution of disease severity category by timepoint and
baseline severity
In the FAS, the proportions of subjects with moderate or severe
insomnia decreased at each time point, and the total proportion of
subjects with subthreshold or no clinically signiﬁcant insomnia
increased correspondingly (Fig. 2A). Among lemborexant-treated
subjects with moderate insomnia at baseline (Fig. 2B), most subjects shifted to less severe insomnia categories after 1 month of
treatment, and 80% or more had subthreshold or no clinically signiﬁcant insomnia (ISI total score 14) from months 6 to 12. At
month 3 and beyond, the majority of lemborexant-treated subjects
with severe insomnia at baseline met criteria for subthreshold or
no clinically signiﬁcant insomnia (Fig. 2C).
4. Discussion
The ﬁndings from these analyses demonstrate a decreased
insomnia severity with lemborexant treatment across 12 months
and support the previously reported beneﬁt of lemborexant on
nighttime measures of insomnia [19,20]. The study also demonstrated that a signiﬁcant number of subjects achieve a meaningful
reduction in insomnia severity as early as 1-month post-treatment
that lasts through at least 12 months.
The responder and remitter analyses in the current study are
important ways to evaluate efﬁcacy. As noted earlier, nearly half of
lemborexant-treated patients were responders (7-point
decrease in ISI score) as early as 1 month post-treatment, which
increased to almost 60% by the 3-month evaluation and persisted
at >50% up to the end of the 12-month analysis. Interestingly, we
did not observe a dose-dependent relationship in responder and
remitter rates with LEM5 and LEM10, nor was a dose response
observed in the analysis of change from baseline in ISI total score.
These ﬁndings suggest that both doses of lemborexant produce
similar efﬁcacy proﬁles. In Study 303, subjects were not permitted
to adjust their lemborexant dose. The recommended starting dose
for lemborexant is 5 mg, however, it is possible that some patients
may derive additional beneﬁt from the higher 10 mg dose,
depending on response and tolerability.
Limited data showing clinically meaningful and signiﬁcant reductions in insomnia severity are available for other DORAs. Of
available responder analyses, treatments are generally reported for
shorter than the 12-month duration shown in the current
lemborexant study. At the approved doses of suvorexant, ISI results are available through 1e3 months of treatment [29e32] and
demonstrate similar outcomes as reported with lemborexant. That
is, a larger proportion of responders (6-point decrease in ISI score
from baseline) [29e31] as well as a higher proportion of remitters
(ISI total score <10) [30] was found for subjects treated
with suvorexant at approved doses versus placebo as assessed at

4.1. Study strengths and limitations
Study 303 was a large, global, multicenter, randomized, doubleblind, parallel-group, placebo-controlled trial that extended
through 12 months of treatment. Few other studies have examined
the long-term impact of insomnia medications on insomnia
severity. Additionally, the use of a well-accepted patient-reported
outcome measure (ie, ISI) to document response and remission in
this study adds to the evidence provided by other metrics (diary
and polysomnography) in documenting the beneﬁcial clinical
impact of lemborexant treatment for insomnia; the ISI may better
reﬂect patients’ subjective complaint than other metrics typically
used for measuring treatment outcome [23,24].
This study enrolled patients using DSM-5 criteria for insomnia
disorder, thus allowing for subjects with some well-managed comorbid conditions, as previously described [19,20]. Therefore, it is
possible that in a subset of subjects, comorbidities may have
contributed to the persistence of moderate to severe insomnia.
Larger studies are needed to deﬁne predictors of “nonresponders.”
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Fig. 2. Distribution of disease severity (based on ISI total score) at each study timepoint for (A) Full Analysis Set (N ¼ 950*) (B) subjects with moderate insomnia (ISI total score 15e21) at
baseline (n ¼ 692), and (C) subjects with severe insomnia (ISI total score 22e28) at baseline (n ¼ 224). ISI total score 0e7, no clinically signiﬁcant insomnia; ISI total score 8e14,
subthreshold insomnia; ISI total score 15e21, moderate insomnia; ISI total score 22e28, severe insomnia. Panels B and C represent shift from moderate or severe (respectively) baseline
severity to each post-treatment severity category at each time point. *One subject was identiﬁed after the full database lock compared with the Period 1 database lock and included in
the post-hoc analysis. Number in parentheses represents the total number of subjects in the corresponding insomnia severity category at the indicated time point. FAS: PBO, n ¼ 319;
LEM5, n ¼ 316; LEM10, n ¼ 315. Subjects with moderate insomnia at baseline: PBO, n ¼ 241; LEM5, n ¼ 222; LEM10, n ¼ 229. Subjects with severe insomnia at baseline: PBO, n ¼ 66;
LEM5, n ¼ 84; LEM10, n ¼ 74. *Of all subjects in the FAS, 34 subjects did not meet ISI inclusion criteria at baseline (ISI total score 8e14, n ¼ 32; ISI total score 0e7, n ¼ 2), although they
met ISI inclusion criteria at screening. FAS ¼ Full Analysis Set; ISI ¼ Insomnia Severity Index; LEM5 ¼ lemborexant 5 mg; LEM10 ¼ lemborexant 10 mg; PBO ¼ placebo.
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Appendix A. Supplementary data

It should be noted that the analyses of responders and remitters,
distribution of disease severity, and participant subgroups with
moderate or severe insomnia were post-hoc analyses.

Supplementary data to this article can be found online at
https://doi.org/10.1016/j.sleep.2022.01.024

5. Conclusions
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decreased the severity of insomnia symptoms, as assessed by
mean ISI total score, and increased the proportions of responders
and remitters. Improvements in insomnia severity were maintained over 12 months of treatment and were seen in the subgroups of subjects with either moderate or severe insomnia
determined at baseline.
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